



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TRC8 (h): 293T Lysate: sc-116907

BACKGROUND

TRC8 (translocation in renal carcinoma on chromosome 8), also known as RNF139 (RING-finger protein 139), RCA1 or HRCA1 (hereditary renal cancer associated 1), is a multi-pass membrane protein that is predominantly expressed in testis, adrenal gland and placenta, and is expressed at lower levels in liver, skeletal muscle, pancreas, kidney, brain, heart and lung. Localizing to the endoplasmic reticulum (ER), TRC8 contains ten transmembrane segments, a sterol-sensing domain and one RING-type zinc finger, and may function as a ubiquitin ligase and signaling receptor. TRC8 physically interacts with VHL (von Hippel-Lindau disease tumor suppressor), and the inhibition of either of these proteins leads to the same ventral midline defect. Disruption of the TRC8 gene, caused by the 3;8 chromosomal translocation, is associated with hereditary renal cell carcinoma (RCC), suggesting that TRC8 is a potential tumor suppressor for RCC. Further supporting its role as a tumor suppressor, TRC8 mediates the induction of G₂/M phase arrest, increased apoptosis and decreased DNA synthesis.

REFERENCES

1. Boldog, F.L., Gemmill, R.M., Wilke, C.M., Glover, T.W., Nilsson, A.S., Chandrasekharappa, S.C., Brown, R.S., Li, F.P. and Drabkin, H.A. 1993. Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. *Proc. Natl. Acad. Sci. USA* 90: 8509-8513.
2. Gemmill, R.M., West, J.D., Boldog, F., Tanaka, N., Robinson, L.J., Smith, D.I., Li, F. and Drabkin, H.A. 1998. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. *Proc. Natl. Acad. Sci. USA* 95: 9572-9577.
3. Lorick, K.L., Jensen, J.P., Fang, S., Ong, A.M., Hatakeyama, S. and Weissman, A.M. 1999. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. *Proc. Natl. Acad. Sci. USA* 96: 11364-11369.
4. Gemmill, R.M., Bemis, L.T., Lee, J.P., Sozen, M.A., Baron, A., Zeng, C., Erickson, P.F., Hooper, J.E. and Drabkin, H.A. 2002. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. *Oncogene* 21: 3507-3516.
5. Charytoniuk, D., Porcel, B., Rodríguez Gomez, J., Faure, H., Ruat, M. and Traiffort, E. 2002. Sonic hedgehog signalling in the developing and adult brain. *J. Physiol.* 96: 9-16.
6. Gemmill, R.M., Lee, J.P., Chamovitz, D.A., Segal, D., Hooper, J.E. and Drabkin, H.A. 2005. Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CAN5. *Oncogene* 24: 3503-3511.
7. Brauweiler, A., Lorick, K.L., Lee, J.P., Tsai, Y.C., Chan, D., Weissman, A.M., Drabkin, H.A. and Gemmill, R.M. 2007. RING-dependent tumor suppression and G₂/M arrest induced by the TRC8 hereditary kidney cancer gene. *Oncogene* 26: 2263-2271.
8. Poland, K.S., Azim, M., Folsom, M., Goldfarb, R., Naeem, R., Korch, C., Drabkin, H.A., Gemmill, R.M. and Plon, S.E. 2007. A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. *Genes Chromosomes Cancer* 46: 805-812.

CHROMOSOMAL LOCATION

Genetic locus: RNF139 (human) mapping to 8q24.13.

PRODUCT

TRC8 (h): 293T Lysate represents a lysate of human TRC8 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

TRC8 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive TRC8 antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

TRC8 (E-12): sc-376358 is recommended as a positive control antibody for Western Blot analysis of enhanced human TRC8 expression in TRC8 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



TRC8 (E-12): sc-376358. Western blot analysis of TRC8 expression in non-transfected: sc-117752 (A) and human TRC8 transfected: sc-116907 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.